Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
From MaRDI portal
Publication:87467
DOI10.1111/1467-9876.00244zbMath1112.62336OpenAlexW2102347194WikidataQ59901772 ScholiaQ59901772MaRDI QIDQ87467
Didier Renard, Helena Geys, Marc Buyse, Geert Molenberghs, Tomasz Burzykowski, Helena Geys, Marc Buyse, Geert Molenberghs, Tomasz Burzykowski, Didier Renard
Publication date: 1 December 2001
Published in: Journal of the Royal Statistical Society Series C: Applied Statistics (Search for Journal in Brave)
Full work available at URL: http://hdl.handle.net/1942/384
Related Items (33)
Center-within-trial versus trial-level evaluation of surrogate endpoints ⋮ Meta-analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling ⋮ Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint ⋮ Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach ⋮ Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials ⋮ Missing data methods in longitudinal studies: a review ⋮ Confirmatory adaptive group sequential designs for single‐arm phase II studies with multiple time‐to‐event endpoints ⋮ A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials ⋮ Testing for Heterogeneity in the Utility of a Surrogate Marker ⋮ Cluster-robust estimators for multivariate mixed-effects meta-regression ⋮ Bayesian ridge regression for survival data based on a vine copula-based prior ⋮ Simplified modeling strategies for surrogate validation with multivariate failure-time data ⋮ Dynamic lifetime prediction using a Weibull-based bivariate failure time model: a meta-analysis of individual-patient data ⋮ Meta-analysis of individual patient data with semi-competing risks under the Weibull joint frailty-copula model ⋮ True endpoint reduction by surrogate endpoints ⋮ Choice of units of analysis and modeling strategies in multilevel hierarchical models ⋮ The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials ⋮ Generalized shared-parameter models and missingness at random ⋮ Statistical evaluation of surrogate endpoints with examples from cancer clinical trials ⋮ Assessing the value of a censored surrogate outcome ⋮ Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data ⋮ On composite marginal likelihoods ⋮ An information-theoretic approach to surrogate-marker evaluation with failure time endpoints ⋮ Unbalanced cluster sizes and rates of convergence in mixed-effects models for clustered data ⋮ On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm ⋮ surrosurv ⋮ Exploring and validating surrogate endpoints in colorectal cancer ⋮ Assessing the numerical integration of dynamic prediction formulas using the exact expressions under the joint frailty-copula model ⋮ Pairwise Fitting of Mixed Models for the Joint Modeling of Multivariate Longitudinal Profiles ⋮ Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling ⋮ Multivariate frailty models for two types of recurrent events with a dependent terminal event: Application to breast cancer data ⋮ Bayesian ridge estimators based on copula-based joint prior distributions for regression coefficients ⋮ Estimation of a common mean vector in bivariate meta-analysis under the FGM copula
This page was built for publication: Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
